S Y N OPSIS Twenty-one of 29 patients suffering from myasthenia gravis derived benefit from a short intensive course of adrenocorticotrophin (ACTH). The mean duration of benefit was approximately six months. The best results were obtained in patients with a short history of myasthenia. Transient deterioration during the course ofinjections was encountered in some cases but necessitated assisted respiration only in patients with severe generalized weakness before treatment.
There have now been several reports of the efficacy of short high dosage ACTH therapy in the management of myasthenia gravis (Soffer et al., 1948; Hellman, 1949; Torda and Wolff, 1951; Grob and Harvey, 1952; Freydberg, 1960; von Reis et al., 1965; Grob and Namba, 1966; Osserman and Genkins, 1966; Cape and Utterbuck, 1969; Gibberd et al., 1971; Liversedge, 1971; Namba et al., 1971; Brunner et al., 1972) . It Careful clinical assessment of the patient's muscular power was carried out before, during, and at intervals after a course of therapy. In view of the widely differing muscular involvement among our cases, the clinical assessment was made firstly on the patient's degree of inability to follow his normal daily routine, and secondly on the examiner's overall impression of the patient's muscular status on examination. The improvement in status relates strictly to a qualitative increase in ability and power, and was not related in any way to the period during which the given improvement was maintained. Thus, good improvement meant that there was a return to normal, or very nearly normal, muscular power and ability to follow normal daily routine. Moderate improvement indicated a substantial increment in Beniefit from adreniocorticotrophin in myasthenia gravis ability and power-falling well short, however, of a return to normal. Slight improvement indicated increment of small but useful degree in ability and power.
With the exception of the patients who deteriorated during the course of ACTH therapy to the extent of requiring assisted respiration, the daily dose of anticholinesterase therapy was left unaltered. In patients requiring assisted respiration, anticholinesterase therapy was conducted on an ad hoc basis but was never completely discontinued.
RESULTS
In the 43 courses given to 29 patients improvement occurred after 36 courses (84%). The mean duration of improvement was 5-7 months. In the 36 instances of benefit, the improvement was graded as good in 11, moderate in 13, and slight in 12. A really satisfactory response was therefore seen in 11 out of 43 courses of treatment in nine out of 29 patients. There was an inverse relationship between the duration of the myasthenia gravis at the time of treatment and improvement after ACTH treatment. Thus patients whose myasthenia was of short duration obtained the best improvement both in quality (Table 2 ) and duration (Table 3) . None of the following factors appeared to have any significant influence on the nature of improvement: sex, age, type or severity of myasthenia, presence of thymic pathology or previous thymectomy, or lack of response to a course of high dose ACTH on a previous occasion.
With regard to deterioration during the course of ACTH, the only factor of relevance was the severity of myasthenia before treatment, in that those more severely affected showed a higher incidence of deterioration (Table 4) . From Table 4 it can also be seen that types IIB and III were the vulnerable groups for deterioration severe enough to necessitate assisted respiration. No significant influence of the following features was found in relation to the occurrence of deterioration during the course of treatment: feel that sodium restriction and potassium supplementation are indicated during the course of high dose ACTH. In this way the chances of sodium retention with oedema and hypertension and of significant hypokalaemia, are minimized. We were interested to see if careful control of sodium and potassium metabolism during the course of treatment in any way influenced the occurrence of deterioration. As mentioned our deterioration rate was fairly low. This could be attributable to the sodium restriction and potassium supplementation which all our patients received during the course of treatment, though it must be stated that some patients in our group did deteriorate during the ACTH therapy without any observed change in sodium balance or serum potassium levels. We were unable to detect any significant difference in sodium and potassium metabolism between the patients who deteriorated and those who did not.
The only factor we could identify which correlated positively with the occurrence of deterioration during the course of ACTH therapy was the severity of the myasthenia at the start of treatment. It is clearly important that respiratory care facilities should be available when treating patients with myasthenia by ACTH, especially when the clinical picture is one of severe affection.
